Volume 94 Issue 44
Issue Date: November 7, 2016
p. 17 ConcentratesIssue Date: November 7, 2016
Lonza will supply Clovis drug
Contract manufacturer Lonza will build a plant in Visp, Switzerland, to supply rucaparib, the active ingredient in Clovis Oncology’s PARP inhibitor. Lonza will open a new production line in 2019 that will provide dedicated supply until 2025. Rucaparib targets cancer by inhibiting the DNA-repair enzymes poly-ADP ribose polymerase-1, 2, and 3. It is under FDA priority review for treating advanced ovarian cancer with a decision to come by February 2017.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society
Leave A Comment